NY-ESO-1 TCR(Kite Pharma)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameNY-ESO-1 TCR(Kite Pharma)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Retroviral vector +[4]

Mechanisms of ActionCancer/testis antigen 1 modulatorsGene transference

TargetsCancer/testis antigen 1

Therapy Area/IndicationsSkin MelanomaSolid tumoursNeoplasm Metastasis +[14]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesKite Pharma National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma Roswell Park Cancer Institute University Of Southern California +[4]

Inactive CompaniesN/A

Active IndicationsSkin MelanomaSolid tumoursUterine Cervical Neoplasms +[13]

Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A